Dual DNMT–EZH2 Inhibition as a Stroma-Directed Strategy in Castration-Resistant Prostate Cancer: A Commentary
Background: Castration-resistant prostate cancer (CRPC) remains a lethal progression state despite androgen-deprivation therapy, driven by epigenetic plasticity and a fibrotic tumour microenvironment. Single-agent epigenetic inhibitors have limited activity in solid tumours, partly because compensatory H3K27me3-mediate...